Sponsored by
This treatment is being considered for approval by the USA FDA next week.. I will be speaking there as a patient advocate. Impressive results: Six-month progression-free survival was achieved in 41% of patients receiving GLIOLAN compared to 21% of patients who were operated on without the use of the drug p=0·0003